Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from January 8, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 8, 2026 — +10.7% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$107.00 – $112.00Entry zone — fair-value band

$111.25Published — price the day we called it

$122.38Target — the price the thesis aimed for

$125.14Peak — highest point inside the window, not a realized return

$123.18Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 28 days.

At window close

+10.7%

realized, from the publication price to the last close inside the window

Peak gain

+12.5%

peak, from the publication price — not a realized return

S&P 500, same window

-1.7%

SPY over the identical days, dividend-adjusted

Window close

$123.18

last close inside the window, ended April 8, 2026

Peak price

$125.14

peak on February 25, 2026 — not a realized return

Days to target

The thesis — published January 8, 2026

Predicted growth

+10%

over the measurement window

Target price

$122.38

the price the thesis aimed for

Entry zone

$107.00 – $112.00

the fair-value band we waited for

Price at publication

$111.25

published January 8, 2026

Confidence

60%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck looks like a short-term defensive growth pick because two recent events could draw attention: an analyst upgrade with a higher price target and the start of a Phase 3 lung cancer trial with calderasib plus Keytruda. Those can bring more buyers, but the stock has already risen, so wait for a pullback before buying.

Primary drivers

Analyst upgrade may attract more institutional buyers
Phase 3 trial start creates news and interest
Works as defensive pharma exposure if markets turn cautious
Recent run raises chance of a short-term pullback; wait to enter

How it played out

MRK: target reached in 28 days

Lyra published MRK at $111.25 on January 8, 2026, with a short-term thesis for 10% growth. The thesis pointed to an analyst upgrade, the start of a Phase 3 lung cancer trial with calderasib plus Keytruda, defensive pharma exposure, and the risk that a recent run could bring a pullback before entry.

Inside the window, MRK reached the $122.38 target in 28 days. It peaked at $125.14 on February 25, a 12.5% gain, and ended the window at $123.18. The published thesis played out. The target was reached, and the closing price stayed above it.

What happened during the window

On February 3, 2026, Merck reported fourth-quarter revenue of $16.4 billion and adjusted earnings of $2.04 per share. It also gave 2026 guidance for revenue of $65.5 billion to $67 billion and adjusted earnings of $5.00 to $5.15 per share.

Merck’s outlook for 2026 comes in below expectations as pipeline faces make-or-break year

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals